Marc Voigt
Vorstandsvorsitzender bei IMMUTEP LIMITED
Vermögen: 3 Mio $ am 30.04.2024
Aktive Positionen von Marc Voigt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMUTEP LIMITED | Direktor/Vorstandsmitglied | 09.07.2014 | - |
Vorstandsvorsitzender | 09.07.2014 | - | |
Finanzdirektor/CFO | 19.11.2012 | - | |
Corporate Officer/Principal | 01.05.2012 | 16.11.2012 | |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - | - |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Vorsitzender | 18.11.2015 | - |
Präsident | 18.11.2015 | - | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Marc Voigt
Ehemalige bekannte Positionen von Marc Voigt
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Finanzdirektor/CFO | 01.06.2001 | 02.01.2006 |
General Counsel | 01.06.2001 | 02.01.2006 | |
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Finanzdirektor/CFO | 01.01.2003 | 02.01.2006 |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Corporate Officer/Principal | - | - |
ELANIX BIOTECHNOLOGIES AG | Direktor/Vorstandsmitglied | 27.10.2016 | - |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology caprotec bioanalytics GmbH commercializes Capture Compound Mass Spectrometry technology. It offers compound profiling services, supplies managing risk services, support the development of the health market and biomarker, rescues projects, selects and optimizes the development processes, and offers collaborations with other companies. The company was founded by Hubert Koester in 2007 and is headquartered in Berlin, Germany. | Geschäftsführer | 13.07.2011 | - |
Finanzdirektor/CFO | 13.07.2011 | - | |
░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Ausbildung von Marc Voigt
Freie Universität Berlin | Masters Business Admin |
Statistik
International
Deutschland | 9 |
Vereinigtes Königreich | 2 |
Australien | 2 |
Operativ
Corporate Officer/Principal | 5 |
Director of Finance/CFO | 4 |
Director/Board Member | 2 |
Sektoral
Health Technology | 7 |
Finance | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ALLIANZ SE | Finance |
IMMUTEP LIMITED | Health Technology |
ELANIX BIOTECHNOLOGIES AG | Health Technology |
Private Unternehmen | 7 |
---|---|
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Health Technology |
Allianz Versicherungs AG
Allianz Versicherungs AG Multi-Line InsuranceFinance Allianz Versicherungs-AG engages in the non-life insurance business. It provides general accident, liability, vehicle, legal expense, fire, credit and surety, as well as transport insurance services. The company is headquartered in Munich, Germany. | Finance |
caprotec bioanalytics GmbH
caprotec bioanalytics GmbH BiotechnologyHealth Technology caprotec bioanalytics GmbH commercializes Capture Compound Mass Spectrometry technology. It offers compound profiling services, supplies managing risk services, support the development of the health market and biomarker, rescues projects, selects and optimizes the development processes, and offers collaborations with other companies. The company was founded by Hubert Koester in 2007 and is headquartered in Berlin, Germany. | Health Technology |
Medical Enzymes AG
Medical Enzymes AG Medical/Nursing ServicesHealth Services Medical Enzymes AG is a privately held innovative biopharmaceutical company with a focus on therapeutically useful enzymes. The company has developed a new product family based on amino acid depleting enzymes. This unique approach is highly effective against cancer - the major target market of Medical Enzymes AG. Medical Enzymes business strategy focuses on the clinical development of therapeutic enzymes until clinical proof of concept and to commercialize those products through collaboration with selected pharmaceutical partners. | Health Services |
Immutep SAS
Immutep SAS Pharmaceuticals: MajorHealth Technology Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France. | Health Technology |
Pharma-Lizenz-Club Deutschland | |
Immutep GmbH
Immutep GmbH BiotechnologyHealth Technology Part of Immutep Ltd., Immutep GmbH develops novel immunotherapy treatments for cancer and autoimmune disease. The company is based in Leipzig, Germany. The CEOs of the German company are - Kaufmann, Marc Voigt, Deanne Miller. | Health Technology |
- Börse
- Insiders
- Marc Voigt
- Erfahrung